Bepreve generic
Bepreve is an ophthalmic drug owned by Bausch And Lomb Inc. This drug has bepotastine besilate as the active ingredient and is available in solution/drops form. Bepreve was first authorized for market use on the 8th of September, 2009.
When will Bepreve generic be available?
Bepreve holds a total of 2 drug patents, out of which 1 has already expired. The other remaining patent, US8784789 titled 'Aqueous liquid preparations and light-stabilized aqueous liquid preparations', is set to expire on 13th January, 2025. Upon its expiry, the generic versions of Bepreve are expected to enter the market.
Bepreve uses
Bepreve's active ingredient, bepotastine besilate, is commonly used to treat eye irritation caused by allergens. The ophthalmic solution is used to reduce the effects of the allergic response, offering relief from itching and inflammation.
Bepreve patent expiration
Bepreve is currently covered under two patents: US8877168, which has expired, and US8784789, expiring on 13th January, 2025. The expected release date of Bepreve generic will be upon the expiry of the latter. Below are the details of the patent: